Search Within

Population Sciences Research Program

  1. "Nursing"
  2. "Meeting abstract"
  3. "Steven Horwitz"
  4. "Maria Palomba"
Formats
  1. Meeting Abstract (16)
Groups
  1. Center for Hematologic Malignancies (16)
  2. Department of Medicine (16)
  3. Hematologic Malignancies, Division of (16)
  4. Lymphoma (16)
  5. Nursing (16)
  6. Survivorship Research (15)

More Groups

People
  1. Andrew Zelenetz (16)
  2. Maria Palomba (16)
  3. Paul Hamlin (16)
  4. Steven Horwitz (16)
  5. Alison Moskowitz (15)
  6. John Gerecitano (15)

More People

Years
  1. 2019 (1)
  2. 2017 (3)
  3. 2016 (4)
  4. 2015 (2)
  5. 2014 (3)
  6. 2013 (1)

More Years

Publications
  1. Blood (11)
  2. Hematological Oncology (2)
  3. Journal of Clinical Oncology (2)
  4. Haematologica (1)
Publishers
  1. American Society of Hematology (11)
  2. American Society of Clinical Oncology (2)
  3. Wiley Blackwell (2)
  4. Ferrata Storti Foundation (1)

Results (16)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A pilot study of brentuximab vedotin combined with AVD chemotherapy and radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L. E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S.; Drill, E.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Time from prognosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma
    Meeting Abstract

    Soumerai, J. D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K. S.; Palomba, M.; Gerecitano, J. F.; Noy, A.; Hamlin, P.; Moskowitz, C. H.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schòˆder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • A Phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M.; Lynch, P.; Scheuerman, M.; Kumar, A.; Gerecitano, J. F.; Zelenetz, A. D.; Hamlin, P. A. Jr; Noy, A.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Outcomes of follicular lymphoma patients by dynamic FLIPI at diagnosis and initial treatment in the post-rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schòˆder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Defining the incidence and clinical impact of genomic alterations across different histologic types of lymphoma using a clinically validated comprehensive targeted sequencing assay
    Meeting Abstract

    Batlevi, C.; Rapaport, F.; Intlekofer, A. M.; Reiner, A.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, L.; Moskowitz, A. J.; Gerecitano, J. F.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma
    Meeting Abstract

    Mehta-Shah, N; Lunning, M. A.; Boruchov, A. M.; Ruan, J.; Nair, S.; Lynch, P.; Byrne, R.; Moskowitz, A. J.; Matasar, M. J.; Gerecitano, J. F.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save